Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
HEAL Initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development (R61/R33 - Clinical Trial Not Allowed)
This FOA invites applications for pre-clinical research to stimulate the development of novel, mechanism-based pharmacotherapies to selectively reverse breathing suppression produced by opioids.
Two critical phases of pre-clinical investigation are supported.
Phase I:
the identification
and rigorous validation of candidate targets; Phase II:
development of therapeutic candidates, such as small molecules, biologics, and natural products that modulate validated targets identified in Phase I, using relevant animal models or human cells/tissue.
Specific Phase I and II milestones, which will be formalized pre-award and serve as a schedule of performance expectations to maximize the output from each phase of the study.
Milestone performance will be a major factor in determining which applications will be selected to transition from Phase I to Phase II.
Phase II extends up to addressing preclinical functional outcomes, toxicology, and pharmacokinetics needed to support an Investigational New Drug (IND) application.
Multi-disciplinary, multiple PI teams combining expertise in respiratory neurobiology, opioid pharmacology and pre-clinical drug development are strongly encouraged.
This FOA is intended for pharmacotherapeutic development.
Projects proposing device and model development or validation, the elucidation of biological mechanisms, population-based epidemiology, or human subjects research would not be responsive.
Reversal of the respiratory depression, without inducing generalized opioid withdrawal, or interfering with analgesic effects addresses the ultimate goal of developing better medical strategies for management of deleterious consequences of synthetic illicit, as well as prescription opioids.
Two critical phases of pre-clinical investigation are supported.
Phase I:
the identification
and rigorous validation of candidate targets; Phase II:
development of therapeutic candidates, such as small molecules, biologics, and natural products that modulate validated targets identified in Phase I, using relevant animal models or human cells/tissue.
Specific Phase I and II milestones, which will be formalized pre-award and serve as a schedule of performance expectations to maximize the output from each phase of the study.
Milestone performance will be a major factor in determining which applications will be selected to transition from Phase I to Phase II.
Phase II extends up to addressing preclinical functional outcomes, toxicology, and pharmacokinetics needed to support an Investigational New Drug (IND) application.
Multi-disciplinary, multiple PI teams combining expertise in respiratory neurobiology, opioid pharmacology and pre-clinical drug development are strongly encouraged.
This FOA is intended for pharmacotherapeutic development.
Projects proposing device and model development or validation, the elucidation of biological mechanisms, population-based epidemiology, or human subjects research would not be responsive.
Reversal of the respiratory depression, without inducing generalized opioid withdrawal, or interfering with analgesic effects addresses the ultimate goal of developing better medical strategies for management of deleterious consequences of synthetic illicit, as well as prescription opioids.
Related Programs
Department of Health and Human Services
National Center on Sleep Disorders Research
Department of Health and Human ServicesDrug Abuse and Addiction Research Programs
Department of Health and Human ServicesCardiovascular Diseases Research
Department of Health and Human ServicesDepartment of Health and Human Services
Blood Diseases and Resources Research
Department of Health and Human Services
Agency: Department of Health and Human Services
Office: National Institutes of Health
Estimated Funding: $500,000
Office: National Institutes of Health
Estimated Funding: $500,000
Who's Eligible
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-031.html
Additional Information of Eligibility:
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U. S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U. S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-031.html
Contact:
Agency Email Description:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Agency Email:
Date Posted:
2020-01-24
Application Due Date:
Archive Date:
2020-04-29
Social Entrepreneurship
Spotlight
This Social Innovation Helps Prevent Bed Sores in Wheelchair Users
Co-founders William Mann and David Mravyan devised the Sensimat during a mandatory project for their MBA at the Richard Ivey School of Business in Canada. Sensimat is a device that helps manage and assess pressure among wheelchair users.
Learn How to Identify and Avoid Grant Scams
